Clinical Trial Update: LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients [Phase 4]

View source ↗

Summary

This is a Phase 4 clinical trial evaluating the LDL-C lowering efficacy and safety of rosuvastatin dosed at 20 mg/day versus 10 mg/day in Chinese patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: Committee of Cardio-Cerebral-Vascular Diseases of GSC | Conditions: Acute Coronary Syndrome | Phase 4 | Status: UNKNOWN